MRMarie-Eve Robinson

Marie-Eve Robinson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marie-Eve Robinson has a total of 172 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Psychiatric Comorbidities and Treatment Modalities in Children With Osteogenesis Imperfecta: A Systematic Review of Mental Health

    by Julia M. Morales, Camille F. Villar, Beatriz Varman, Gianna M. Colombo, Danqi Li, Sarah J. Sadek, Marie‐Eve Robinson, Chaya N. Murali, Kara Ayers, Jocelyn Gomez, et al.

    To evaluate the prevalence of psychiatric signs and symptoms and describe psychotherapeutic and psychopharmacological interventions among children with osteogenesis imperfecta (OI). PRISMA guidelines were followed, and the study was registered in PROSPERO (CRD42024588284). Studies ( n = 1419) were identified across five databases. Eligible studies, identified by independent reviewers, included peer‐reviewed research on psychiatric comorbidities or interventions in children with OI. Data extraction included study design, population characteristics, mental health outcomes, and treatment effectiveness, with all studies assessed for quality and bias. Findings were synthesized to evaluate the prevalence of psychiatric comorbidities and intervention effectiveness. Five articles met inclusion criteria after screening and full‐text review. Although the included studies varied in design and outcome measures, they reported elevated signs and symptoms of anxiety and depression in children with OI, particularly those with severe phenotypes. Qualitative findings highlighted subclinical psychosocial burdens, including emotional distress and social isolation. No studies evaluated psychotherapeutic or psychopharmacological interventions. This systematic review provides the first comprehensive analysis of psychiatric comorbidities in children with OI, revealing a critical lack of research on psychiatric comorbidities in children with OI. These gaps highlight an urgent need for targeted mental health studies to inform screening and integrated care for this population.

  • Osteogenesis imperfecta and the family: A qualitative analysis of the experiences of family and caregivers.

    by Gianna M. Colombo, Andrew D. Wiese, Amelia E. Mercado, Whitney S. Shepherd, Michelle Fynan, Kara Ayers, W. Conor Rork, Kristin M. Kostick-Quenet, Dianne Nguyen, Sophie C. Schneider, et al.

    Osteogenesis imperfecta (OI) describes a group of rare, heritable bone disorders causing bone fragility, tendency to fracture with minimal trauma, and chronic pain due to abnormal collagen synthesis. Limited research exists on the psychosocial impact of OI during childhood on caregivers and families. This study aimed to understand caregiver experiences, existing social support provided for families affected by OI, and the impact of OI on family life. Thirteen caregivers of individuals with OI participated in semistructured interviews. Researchers coded, abstracted, and analyzed qualitative data to develop themes on the psychosocial impact of OI on the family unit. Analysis yielded four themes: (a) encountering difficult experiences during diagnosis of OI, (b) caregiver well-being and coping, (c) broad family impact, and (d) the existence and further need for social support. Findings have implications for child and caregiver well-being and health care professionals during diagnosis and emphasize the need for social support for families affected by OI. Future research should engage a more diverse (in terms of ethnoracial demographics and family structures) sample and utilize quantitative analyses to complement the present understanding of the relationship between OI and family well-being. (PsycInfo Database Record (c) 2025 APA, all rights reserved).


  • Open Access

    Mindful Self-Compassion to Reduce Pain Interference Among Adults with Osteogenesis Imperfecta

    by Amena Sediqi, Roya Al-Khalili, Saunya Dover, Corien Peeters, Adam Khalif, V. Reid Sutton, Frank Rauch, Brendan Lee, Eric A. Storch, Marie-Eve Robinson

    Between 60 and 80% of adults with osteogenesis imperfecta (OI) experience chronic pain and associated interference. Currently available pain therapies often provide marginal efficacy. Mindful self-compassion (MSC) has emerged as a promising intervention for coping with chronic pain. We conducted a single-center 8-week pilot intervention study to assess the feasibility and acceptability of a MSC program among adults with OI and co-occurring chronic pain. Individuals attended the validated MSC course consisting of 8 weekly virtual 2-h sessions. Participants completed a battery of validated questionnaires assessing pain, various aspects of well-being, and physical function at baseline and post-intervention. Participants wore the ActiGraph GT9X Link watch to measure sleep duration and sleep efficiency. Seven adults with OI and co-occurring pain participated in the MSC program. The program was feasible, as indicated by high attendance and high questionnaire completion rates. Participants reported a mean ± standard deviation (SD) of 3.5 out of 5 ± 0.4 on the Intervention Acceptability Framework. 86% (6/7) of participants found the MSC program to be acceptable. While our pilot study was not powered to show efficacy, we observed a decrease in pain interference on the PROMIS pain interference questionnaire (mean 55.9 ± 5.5 at baseline vs. 50.0 ± 7.3 at 8 weeks). Implementation of the MSC program is feasible as a potential therapeutic option to address chronic pain in OI.


  • Impacting the physical activity confidence of children with medical conditions or disabilities: A randomized controlled trial

    by Hana Alazem, Jenna Yaraskavitch, Angelica Blais, Anna M McCormick, Jane Lougheed, Christine Lamontagne, Kristian B Goulet, Anne Tsampalieros, Leanne M Ward, Sherri Lynne Katz, et al.

    Objectives: Youth with medical conditions or disabilities (MCD) seldom achieve healthy physical activity recommendations. Barriers include a perceived lack of competence, fear of pain/symptom exacerbation, or physical function changes. A 12-week intervention targeting physical activity confidence was evaluated among youth with MCD. Methods: This three-arm randomized controlled trial (in-person/virtual/control) enrolled youth (8 to 18 years) requiring ongoing medical care from tertiary paediatric clinics. Readiness Ruler (motivation ≥4/10, confidence ≤8/10) determined eligibility. Blinded assessments (0, 3, and 6 months) were total motivation/confidence (Canadian Assessment of Physical Literacy), physical activity (7-day accelerometry), screen time, and sleep behaviours. Intervention (2 h × 12 weeks, in-person or virtual) combined game/sport skills with activity participation and education. Results: Sixty-three youth (of 111 randomized) with baseline total motivation/confidence below recommended levels among 31 children and 32 adolescents (51% male, mean age 13.1 ± 3.0 years). In a model adjusted for age and baseline confidence, activity confidence at 3 months was higher among in-person intervention participants compared with control participants (beta = 1.7 [95% Confidence Interval (CI): 0.3, 3.1], P = 0.02). Higher confidence was associated with higher physical activity (r = 0.30; P = 0.01) and decreased sedentary time (r = 0.74; P < 0.001). Conclusions: Youth who were confident were more likely to engage in physical activity. The in-person intervention increased participants’ activity confidence. The limited impact of the virtual format suggests that implementing new skills with peers is critically important for enhancing activity confidence. Further research is required to evaluate whether confidence gains could be sustained beyond the study intervention, would longitudinally increase activity participation over time, or would transfer to other activity settings. Clinical trial registration: The study was registered at ClinicalTrials.gov (NCT04106154).


  • Open Access

    Characterization of Primary IGF-1 Deficiency in a Cohort of Canadian Children with Short Stature Using a Novel Algorithm Tailored to Electronic Medical Records

    by Rinila Haridas, Carly Baxter, Saunya Dover, Ellen B. Goldbloom, Ivan Terekhov, Marie-Eve Robinson

    (1) Background: Severe primary insulin-like growth factor-I deficiency (SPIGFD) is a rare disorder causing short stature in children due to low insulin-like growth factor 1 (IGF-1) levels. Given the sparsity of reported cases of SPIGFD worldwide, the condition may be underdiagnosed, potentially preventing affected children from receiving therapy with recombinant human IGF-1 (rhIGF-1). Our objective was to determine the prevalence of SPIGFD among children with short stature at a large pediatric tertiary care center through the use of a novel electronic medical record (EMR) algorithm. (2) Methods: We queried our EMR using an algorithm that detected all children seen at our center between 1 November 2013 and 31 August 2021 with short stature and low IGF-1. We then conducted chart reviews, applying established diagnostic criteria for those identified with potential SPIGFD. (3) Results: From a cohort of 4863 children with short stature, our algorithm identified 30 (0.6%) patients with potential SPIGFD. Using chart reviews, we determined that none of these patients had SPIGFD. (4) Conclusions: Our algorithm can be used in other EMRs to identify which patients are likely to have SPIGFD and thus benefit from treatment with rhIGF-1. This model can be replicated for other rare diseases.

  • Open Access

    Teaching Adolescents With Type 1 Diabetes Self-Compassion (TADS) to Reduce Diabetes Distress: Protocol for a Randomized Controlled Trial

    by Saunya Dover, Alexandra Ahmet, Karen Bluth, Brian M Feldman, Ellen B Goldbloom, Gary S Goldfield, Sarah Hamilton, Omar Imran, Adam Khalif, Karine Khatchadourian, et al.

    Background: Adolescents living with type 1 diabetes (T1D) often experience diabetes distress (DD), a construct distinct from depression or anxiety that refers to the negative emotions that arise from living with and managing diabetes. Self-compassion, which involves being open to one’s own suffering and treating oneself with the same care one would show to loved ones, is associated with better psychological and clinical outcomes among individuals with T1D. Self-compassion is a skill that can be taught and therefore represents an opportunity for intervention. Objective: The overall aim of this study is to assess the effectiveness of a web-based mindful self-compassion for teens (MSC-T) intervention on improving DD, anxiety, depression, diabetes-related disordered eating, and suicidal ideation experienced by youth with T1D (aged between 12 and 17 years) compared with a waitlist control group (standard of care). We will also explore (1) if the effect of the MSC-T intervention changes over time, (2) if the MSC-T intervention has a positive impact on measures of glycemic control, and (3) if the effect of the MSC-T intervention differs based on self-reported gender. Methods: We will conduct a single-center, parallel-group randomized controlled trial of 140 adolescents with T1D followed for 12 months. Participants will be randomly allocated (using hidden allocation) in a 1:1 ratio to either the MSC-T intervention or the waitlist control group. Our primary outcome is DD, as measured by the Problem Areas in Diabetes-Teen (PAID-T) version at 3 months. Secondary outcomes, assessed at 3 and 12 months, include anxiety (Generalized Anxiety Disorder 7-item [GAD-7] scale), depression (Patient Health Questionnaire-9 [PHQ-9]), diabetes-related disordered eating (Diabetes Eating Problem Survey-Revised [DEPS-R] version), and suicidal ideation (using 1 question from the PHQ-9). Results: Study recruitment began in October 2022 and was completed in March 2023, with a total of 141 participants enrolling. Data collection will be ongoing until March 2024. The first results are expected in June 2024. Conclusions: This study will be the first randomized trial to assess the effectiveness of the web-based MSC-T intervention on adolescents with T1D. Given that adolescence is a period where individuals are typically required to assume more responsibility for their diabetes care, providing adolescents with the tools they need to better manage the stress that often accompanies T1D management is paramount. Trial Registration: ClinicalTrials.gov NCT05463874; https://clinicaltrials.gov/study/NCT05463874 International Registered Report Identifier (IRRID): DERR1-10.2196/53935


  • Open Access

    Teaching Adolescents With Type 1 Diabetes Self-Compassion (TADS) to Reduce Diabetes Distress: Protocol for a Randomized Controlled Trial (Preprint)

    by Saunya Dover, Alexandra Ahmet, Karen Bluth, Brian M Feldman, Ellen B Goldbloom, Gary S Goldfield, Sarah Hamilton, Omar Imran, Adam Khalif, Karine Khatchadourian, et al.

    BACKGROUND Adolescents living with type 1 diabetes (T1D) often experience diabetes distress (DD), a construct distinct from depression or anxiety that refers to the negative emotions that arise from living with and managing diabetes. Self-compassion, which involves being open to one’s own suffering and treating oneself with the same care one would show to loved ones, is associated with better psychological and clinical outcomes among individuals with T1D. Self-compassion is a skill that can be taught and therefore represents an opportunity for intervention. OBJECTIVE The overall aim of this study is to assess the effectiveness of a web-based mindful self-compassion for teens (MSC-T) intervention on improving DD, anxiety, depression, diabetes-related disordered eating, and suicidal ideation experienced by youth with T1D (aged between 12 and 17 years) compared with a waitlist control group (standard of care). We will also explore (1) if the effect of the MSC-T intervention changes over time, (2) if the MSC-T intervention has a positive impact on measures of glycemic control, and (3) if the effect of the MSC-T intervention differs based on self-reported gender. METHODS We will conduct a single-center, parallel-group randomized controlled trial of 140 adolescents with T1D followed for 12 months. Participants will be randomly allocated (using hidden allocation) in a 1:1 ratio to either the MSC-T intervention or the waitlist control group. Our primary outcome is DD, as measured by the Problem Areas in Diabetes-Teen (PAID-T) version at 3 months. Secondary outcomes, assessed at 3 and 12 months, include anxiety (Generalized Anxiety Disorder 7-item [GAD-7] scale), depression (Patient Health Questionnaire-9 [PHQ-9]), diabetes-related disordered eating (Diabetes Eating Problem Survey-Revised [DEPS-R] version), and suicidal ideation (using 1 question from the PHQ-9). RESULTS Study recruitment began in October 2022 and was completed in March 2023, with a total of 141 participants enrolling. Data collection will be ongoing until March 2024. The first results are expected in June 2024. CONCLUSIONS This study will be the first randomized trial to assess the effectiveness of the web-based MSC-T intervention on adolescents with T1D. Given that adolescence is a period where individuals are typically required to assume more responsibility for their diabetes care, providing adolescents with the tools they need to better manage the stress that often accompanies T1D management is paramount. CLINICALTRIAL ClinicalTrials.gov NCT05463874; https://clinicaltrials.gov/study/NCT05463874 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/53935

  • Open Access

    Standardized growth charts for children with osteogenesis imperfecta

    by Marie-Eve Robinson, Damian Rauch, Francis H. Glorieux, Frank Rauch

    Background Osteogenesis imperfecta (OI) is associated with short stature, which is mild, severe and moderate in OI types I, III and IV, respectively. Standardized OI type- and sex-specific growth charts across all pediatric ages do not exist. Methods We assessed 573 individuals with OI (type I, III or IV), each with at least one height measurement between ages 3 months and 20 years (total 6523 observations). Analogous to the Centers for Disease Control pediatric growth charts, we generated OI type- and sex-specific growth charts for infants (ages 3–36 months) as well as children and adolescents (ages 2–20 years). Growth curves were fitted to the data using the LMS method and percentiles were smoothed. Results Age was associated with a decline in height z-scores (p < 0.001 for all OI types), which was more pronounced in females. Height multiplier curves were produced to predict adult height in children with OI. Among individuals with OI type I, those with COL1A1 pathogenic variants leading to haploinsufficiency were taller than those with COL1A1 or COL1A2 pathogenic variants not leading to haploinsufficiency. Conclusion Our standardized OI type- and sex-specific growth charts can be used to assess the growth of individuals with OI from infancy to adulthood. Impact Standardized osteogenesis imperfecta (OI) type- and sex-specific growth charts across all pediatric ages do not exist. Our study is the first to generate OI type- and sex-specific growth charts across all pediatric ages. Our height multiplier curves can be utilized to predict adult height in children with OI.


  • Open Access

    Sickle cell bone disease and response to intravenous bisphosphonates in children

    by C. Grimbly, P. Diaz Escagedo, J. L. Jaremko, A. Bruce, N. Alos, M. E. Robinson, V. N. Konji, M. Page, M. Scharke, E. Simpson, et al.

    Summary Children with sickle cell disease (SCD) have the potential for extensive and early-onset bone morbidity. This study reports on the diversity of bone morbidity seen in children with SCD followed at three tertiary centers. IV bisphosphonates were effective for bone pain analgesia and did not trigger sickle cell complications. Introduction To evaluate bone morbidity and the response to intravenous (IV) bisphosphonate therapy in children with SCD. Methods We conducted a retrospective review of patient records from 2003 to 2019 at three Canadian pediatric tertiary care centers. Radiographs, magnetic resonance images, and computed tomography scans were reviewed for the presence of avascular necrosis (AVN), bone infarcts, and myositis. IV bisphosphonates were offered for bone pain management. Bone mineral density was assessed by dual-energy X-ray absorptiometry (DXA). Results Forty-six children (20 girls, 43%) had bone morbidity at a mean age of 11.8 years (SD 3.9) including AVN of the femoral (17/46, 37%) and humeral (8/46, 17%) heads, H-shaped vertebral body deformities due to endplate infarcts (35/46, 76%), and non-vertebral body skeletal infarcts (15/46, 32%). Five children (5/26, 19%) had myositis overlying areas of AVN or bone infarcts visualized on magnetic resonance imaging. Twenty-three children (8/23 girls) received IV bisphosphonate therapy. They all reported significant or complete resolution of bone pain. There were no reports of sickle cell hemolytic crises, pain crises, or stroke attributed to IV bisphosphonate therapy. Conclusion Children with SCD have the potential for extensive and early-onset bone morbidity. In this series, IV bisphosphonates were effective for bone pain analgesia and did not trigger sickle cell complications.


  • Pubertal growth in osteogenesis imperfecta caused by pathogenic variants in COL1A1/COL1A2

    by Marie-Eve Robinson, Damian Rauch, Francis H. Glorieux, Frank Rauch